268 related articles for article (PubMed ID: 32820851)
1. P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap.
Smigielski L; Kometer M; Scheidegger M; Stress C; Preller KH; Koenig T; Vollenweider FX
Hum Brain Mapp; 2020 Dec; 41(17):4982-4996. PubMed ID: 32820851
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
[TBL] [Abstract][Full Text] [Related]
3. Effects of psilocybin on time perception and temporal control of behaviour in humans.
Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin.
Bernasconi F; Schmidt A; Pokorny T; Kometer M; Seifritz E; Vollenweider FX
Cereb Cortex; 2014 Dec; 24(12):3221-31. PubMed ID: 23861318
[TBL] [Abstract][Full Text] [Related]
5. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
Kometer M; Schmidt A; Jäncke L; Vollenweider FX
J Neurosci; 2013 Jun; 33(25):10544-51. PubMed ID: 23785166
[TBL] [Abstract][Full Text] [Related]
6. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects.
Smigielski L; Scheidegger M; Kometer M; Vollenweider FX
Neuroimage; 2019 Aug; 196():207-215. PubMed ID: 30965131
[TBL] [Abstract][Full Text] [Related]
7. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.
Preller KH; Pokorny T; Hock A; Kraehenmann R; Stämpfli P; Seifritz E; Scheidegger M; Vollenweider FX
Proc Natl Acad Sci U S A; 2016 May; 113(18):5119-24. PubMed ID: 27091970
[TBL] [Abstract][Full Text] [Related]
8. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
Stenbæk DS; Madsen MK; Ozenne B; Kristiansen S; Burmester D; Erritzoe D; Knudsen GM; Fisher PM
J Psychopharmacol; 2021 Apr; 35(4):459-468. PubMed ID: 33501857
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
[TBL] [Abstract][Full Text] [Related]
10. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
Carter OL; Pettigrew JD; Hasler F; Wallis GM; Liu GB; Hell D; Vollenweider FX
Neuropsychopharmacology; 2005 Jun; 30(6):1154-62. PubMed ID: 15688092
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
[TBL] [Abstract][Full Text] [Related]
12. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
Kometer M; Pokorny T; Seifritz E; Volleinweider FX
Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
[TBL] [Abstract][Full Text] [Related]
14. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
Umbricht D; Vollenweider FX; Schmid L; Grübel C; Skrabo A; Huber T; Koller R
Neuropsychopharmacology; 2003 Jan; 28(1):170-81. PubMed ID: 12496954
[TBL] [Abstract][Full Text] [Related]
15. Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex.
Brockett AT; Francis NA
J Neurophysiol; 2024 Jul; 132(1):45-53. PubMed ID: 38810366
[TBL] [Abstract][Full Text] [Related]
16. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
[TBL] [Abstract][Full Text] [Related]
18. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
Carter OL; Burr DC; Pettigrew JD; Wallis GM; Hasler F; Vollenweider FX
J Cogn Neurosci; 2005 Oct; 17(10):1497-508. PubMed ID: 16269092
[TBL] [Abstract][Full Text] [Related]
19. Enhanced repertoire of brain dynamical states during the psychedelic experience.
Tagliazucchi E; Carhart-Harris R; Leech R; Nutt D; Chialvo DR
Hum Brain Mapp; 2014 Nov; 35(11):5442-56. PubMed ID: 24989126
[TBL] [Abstract][Full Text] [Related]
20. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.
Schmidt A; Kometer M; Bachmann R; Seifritz E; Vollenweider F
Psychopharmacology (Berl); 2013 Jan; 225(1):227-39. PubMed ID: 22836372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
